Quarterly Report – period ended 30 September 2025

Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth and strong commercial progress. Key highlights for the quarter include:

Record revenue for the quarter of $3.0 million driven primarily by Remplir’s growing market penetration in Australia and Singapore
Orthocell maintains robust cash reserves of $27 million in cash as at 30 September 2025 and is well-positioned for continued commercial expansion
Remplir rollout in the US$1.6 Billion US market ahead of schedule, with Distribution networks now spanning 25 states and reaching 40% of the US population, and first surgeries complete
First distributor appointed for Remplir in US$75 million Canadian market, with first sales targeted for December 2025 Quarter
Remplir used in nerve-sparing prostate cancer surgery
Remplir study results deliver compelling 81% success rate
Strengthened leadership with Executive and Board appointments

Orthocell CEO and MD, Paul Anderson, said: “We have continued to build strong commercial momentum in the September quarter with another record quarter of sales revenue delivered primarily from Remplir sales in our existing markets in Australia and Singapore.” Click to read the ASX release.

We detected you're visiting from Australia. Would you like to switch to the AU version of this site?